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Patients with early stage high-risk prostate cancer (prostate specific antigen>20, Gleason
score> 7) are at high risk of recurrence following prostate cancer irradiation. Radiation dose
escalation to the prostate may improve biochemical-free survival for these patients. How-
ever, high rectal and bladder dose with conventional three-dimensional conformal radio-
therapy may lead to excessive gastrointestinal and genitourinary toxicity. Image-guided
radiotherapy (IGRT), by virtue of combining the steep dose gradient of intensity-modulated
radiotherapy and daily pretreatment imaging, may allow for radiation dose escalation and
decreased treatment morbidity. Reduced treatment time is feasible with hypo-fractionated
IGRT and it may improve patient quality of life.
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INTRODUCTION
Prostate cancer is currently detected at an early stage because of
routine screening for prostate specific antigen (PSA) in elderly
males (1). Patients with low-risk early stage prostate cancer
(PSA< 10, Gleason score< 5) demonstrate optimal results when
treated with surgery or radiotherapy. However, in high-risk early
stage prostate cancer patients (PSA> 20, Gleason score> 7), the
current recommendation is androgen suppression therapy com-
bined with radiotherapy because of potential for local recur-
rences and distant metastases (2). Increasing radiation dose to the
prostate may improve local control and survival of these patients
(3). However, normal organs adjacent to the prostate specifically
the rectum, and bladder also receive a high radiation dose with
dose escalation using the conventional three-dimensional confor-
mal radiotherapy (3D-CRT) technique,which leads to a higher risk
of complications (3). Thus, a radiotherapy technique that allows
radiation dose escalation to the prostate while minimizing radia-
tion to the rectum and bladder may improve the therapeutic ratio.
Intensity-modulated radiotherapy (IMRT) has been introduced
recently to decrease excessive radiation dose to the normal organs
near the prostate cancer because of the steep dose gradient away
from the target (4). Compared to 3D-CRT, IMRT may increase sur-
vival rates in patients with high-risk disease because of reduced
rectal volume irradiated over 70 Gy and significantly decreased
gastrointestinal (GI) toxicity, thus allowing radiation dose esca-
lation to the tumor (5). However, in radiation dose escalation
trials for prostate cancer, patients who had higher rectal doses
during IMRT were still at an increased risk of long-term rectal
complications (6). Inclusion of a large rectal volume in the IMRT
planning treatment volume (PTV) may be required to avoid a mar-
ginal miss and therefore lead to excessive rectal irradiation. The
introduction of image-guided radiotherapy (IGRT), which com-
bines the normal tissue sparing effect of IMRT and daily imaging,
has been proven to decrease further radiation dose to the normal
organs without compromising local control in head and neck can-
cer (7–9). Thus, IGRT may allow for radiation dose escalation in
patients with early stage high-risk prostate cancer and improve
biochemical-free survival while reducing treatment toxicity.
www.frontiersin.org February 2015 | Volume 5 | Article 18 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nguyen et al. IGRT and prostate cancer
TECHNIQUES OF PROSTATE CANCER RADIATION THERAPY
DELIVERY WITH IGRT
Currently, many systems are used for daily imaging and may
be classified as invasive and non-invasive. In the invasive sys-
tems, metallic markers are implanted into the prostate as fiducial
markers (FM) to guide radiation delivery. Usually, three seeds
are implanted under ultrasound (US) guidance into the prostate
before CT planning. Daily MV or kV CT are performed to align
the seeds to the planning CT before each treatment. Alternatively,
the seeds can be tracked in real time imaging with a robotic sys-
tem (Cyberknife) or through electromagnetic waves emitted by
the transponders (Calypso System), and allow accurate radiation
delivery even though the prostate moves during treatment. In the
non-invasive system, the prostate position before treatment can
be detected either by US or by CT scan. The patient is shifted for
set-up discrepancies and additional images are obtained to ver-
ify treatment accuracy. The US system is inexpensive, simple, and
non-radiation-based, but is operator-dependent. The CT system
provides either kV or MV imaging. Fan beam kV CT uses a diag-
nostic CT scan alongside the linear accelerator. Cone beam kV CT
uses a gantry mounted kV source and a flat panel detector. A series
of kV X-rays are taken when the gantry rotates and a 3D image
is reconstructed. Image quality is superior with fan beam kV CT
compared to cone beam CT, but the couch needs to be displaced
between imaging and treatment, which may lead to positioning
error. In the MV CT system, the imaging is performed by the
treatment beam that rotates around the patient while the couch
moves (helical Tomotherapy).
Image quality is inferior with MV CT compared to kV CT, but
there are no metal artifacts, which may be helpful if the patient
has hip prosthesis. The latest technology for tumor imaging is
based on magnetic resonance imaging (MRI), which involves a
hybrid Cobalt linear accelerator and an MRI (ViewRay). This is a
promising technology for prostate cancer IGRT, as MRI provides
better imaging of the prostate gland compared to CT scans. Fur-
thermore, MRI allows visualization of gross tumor volume (GTV)
inside the prostate and may enable a higher radiation dose using
the simultaneous integrated boost (SIB) technique.
REDUCTION OF PROSTATE CANCER TREATMENT MORBIDITY
ASSOCIATED WITH ACCURATE IMAGE GUIDANCE
Preliminary evidence suggests that better visualization of the
prostate during radiotherapy leads to improved patient quality of
life (QOL) because of the increased accuracy of radiation delivery.
In a study of 282 prostate cancer patients treated with 3D-CRT
with (n= 154) and without image guidance (n= 128), procti-
tis severity was significantly reduced with image guidance (10).
Patients who had image guidance underwent prostate FM place-
ment and MRI imaging before radiotherapy planning to outline
the target volume. Rectal and urinary dysfunction during radio-
therapy was assessed with QOL questionnaires. Despite a higher
tumor dose to the prostate, patients treated with image guidance
experienced less diarrhea and rectal pain compared to the ones
who did not undergo IGRT. During radiotherapy, the prostate
position changes daily depending on bladder and rectal filling.
Accurate target localizing with intra-prostate FM instead of bony
landmark fusion leads to a decreased volume of bladder and
rectum being irradiated to a high dose and therefore a reduction
of acute morbidity. Gill et al. (11) reported significant reduction
in severe urinary frequency, diarrhea, and fatigue in patients with
prostate cancer who were treated with IGRT (n= 265) compared
with patients not treated with IGRT (n= 26). Both groups were
treated with IMRT using the same constraints and PTV mar-
gins. The prostate dose was higher for the group treated with
IGRT (78 Gy) compared to those treated without IGRT (74 Gy).
Thus, regardless of the radiotherapy technique, accurate localiza-
tion of the prostate before treatment decreases treatment toxicity
by eliminating the geographic miss of the prostate, which would
lead to an excessive radiation dose to the adjacent non-involved
normal structures. Other studies have corroborated the image
guidance effects on sparing normal organs in patients with prostate
cancer (12, 13).
RADIATION DOSE ESCALATION FOR HIGH-RISK PROSTATE
CANCER PATIENTS TREATED WITH IGRT AND
CONVENTIONAL FRACTIONATION
In patients with high-risk prostate cancer, long-term follow-up
suggests that a radiation dose ≥80–81 Gy to the tumor bed may
be required for long-term biochemical control (14, 15). The effect
of radiation dose escalation may be independent of hormonal
therapy (15). Radiation doses up to 86.4 Gy were determined to
be feasible with limited toxicity in prostate cancer patients treated
with IMRT (16). In a study of 1,002 prostate cancer patients treated
to 86.4 Gy with IMRT, late grade 3 GI and genitourinary (GU) tox-
icities were reported (0.7 and 2.2%, respectively). However, acute
grade 3–4 toxicities were not reported in the study. Thus, IGRT
may allow for radiation dose escalation and further reduction of
normal tissue toxicity by combining IMRT and daily imaging.
Indeed, preliminary evidence suggests that IGRT as a safe radio-
therapy technique for radiation dose escalation in patients with
prostate cancer. Takeda et al. (17) reported no acute grade 3–4
toxicities in 141 patients with intermediate or high-risk localized
prostate cancer when the radiation dose was increased from 76 Gy
(n= 13) to 80 Gy (n= 128). Only two patients developed long-
term grade 3 toxicities. Kok et al. (18) compared late toxicities
among 311 patients treated with IMRT for prostate cancer with-
out image guidance (74 Gy) and with image guidance (78 Gy).
Despite a higher radiation dose in this study, late GI toxicities were
significantly reduced in patients with image guidance. In a similar
study comparing IGRT (78 Gy) and 3D-CRT (76 Gy) for high-
risk prostate cancer, late GI and GU toxicities were significantly
decreased for patients treated with IGRT (19).
RADIATION DOSE ESCALATION FOR HIGH-RISK PROSTATE
CANCER PATIENTS TREATED WITH IGRT AND
HYPOFRACTIONATION
Prostate cancer cells are characterized by a low α/β ratio rang-
ing from 0.8 to 2.2 Gy, suggesting that delivering a radiation dose
higher than the conventional fractionation of 1.8–2 Gy/day may
be more effective for cancer cell killing. On the opposite side
is the risk of normal tissue injury associated with high dose
hypofractionation. However, if the volume of rectal and blad-
der tissue exposed to a high radiation dose can be reduced with
high precision radiation delivery, hypofractionation may be an
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ideal radiation technique to reduce treatment time while poten-
tially improving the biochemical control in patients with high-risk
prostate cancer. Jerekzek-Fossa et al. (20) compared the acute tox-
icity of 179 prostate cancer patients treated with IGRT [70.2 Gy
in 2.7 Gy/fraction (84.2 Gy dose equivalent in 2 Gy/fraction)] and
174 patients treated with 3D-CRT (80 Gy in 2 Gy fraction). There
was no significant difference in toxicity between the two groups
of patients. In a follow-up study, QOL of the patients treated
with hypo-fractionated IGRT was not significantly affected long-
term, thus illustrating that IGRT may be beneficial in patients with
high-risk prostate cancer (21). A similar radiation dose escalation
study was performed in 48 prostate cancer patients using regimens
of 68.04 Gy at 2.52 Gy/fraction (n= 32), 70 Gy at 2.5 Gy/fraction
(n= 5), and 70.2 Gy at 2.6 Gy/fraction. No patients developed
grade 3–4 late toxicities (22). The safety of IGRT for hypofrac-
tionation was also corroborated in another study where patients
with high-risk prostate cancer were treated up to 74.2 Gy in
2.65 Gy/fraction with the SIB technique. Only 1 out of 70 patients
developed an acute grade 3 rectal reaction (23). A preliminary
report from a randomized study comparing high dose hypofrac-
tionation to conventional fractionation with IGRT suggests that
hypo-fractionation may allow for a higher radiobiologic dose
without increasing treatment toxicity for high-risk prostate can-
cer patients. Patients (n= 124) were recruited and treated to 76 Gy
in 2 Gy/fraction (n= 57) and 63 Gy in 3.15 Gy/fraction (n= 67)
equivalent to 84 Gy in 2 Gy/fraction to the prostate with the SIB
technique (24). There was no significant difference in acute tox-
icities between the two arms suggesting that IGRT may confer
effective normal tissue sparing but long-term follow-up is needed
as complications may develop later.
The extreme hypo-fractionation scheme for high-risk prostate
cancer involves continuous tracking of the prostate with two
orthogonal X-ray imagers that allow a tight PTV margin pos-
teriorly (3 mm) while multiple non-coplanar beams improve the
plan conformity compared to IMRT (Cyberknife) (25). Total treat-
ment time can be reduced to 1 week instead of the conventional
8–9 weeks of treatment as the volume of rectum and bladder
exposed to high radiation dose can be minimized. In addition,
if treatment toxicity can be reduced, a high dose to the prostate
may be feasible to improve local control. Oliai et al. (26) reported
the acute toxicity and long-term complications of 70 patients with
low- to high-risk prostate cancer treated with radiation dose esca-
lation by Cyberknife (CK) ranging from 35 Gy in 7 Gy/fraction
(n= 5), 36.25 Gy in 7.25 Gy/fraction (n= 36), and 37.5 Gy in
7.5 Gy/fraction (n= 29). Acute and late grade 3 GU toxicities were
4 and 3%, respectively. None of the patients experienced grade 3–4
toxicities at a median follow-up of 31 months. Katz et al. (27) also
corroborated the low toxicity of CK for prostate cancer. Among 304
patients with low (n= 211), intermediate (n= 81), and high-risk
(n= 12) prostate cancer treated with CK to 35 Gy in 7 Gy/fraction
(n= 50) and 36.25 Gy in 7.25 Gy/fraction (n= 254), none of the
patients developed acute grade 3–4 toxicity. At a median follow-
up of 60 months, only 2% of the patients developed long-term
grade 3 GU toxicity. A follow-up study suggested that prostate
cancer patients treated with this fractionation on CK had QOL
similar to that observed in conventional fractionation (28). Even
though most patients treated with CK hypo-fractionation had low
to intermediate risk prostate cancer, late grade 3 GI and GU toxi-
cities ranged from 0 to 3%, which confirmed the safety of CK for
radiation dose escalation (29–34). The high radiobiologic equiva-
lent dose of 92 Gy (corresponding to 35 Gy in 7 Gy/fraction with
an α/β ratio of 1.5) or higher with hypo-fractionated CK sug-
gests that this radiotherapy technique may be potentially effective
for high-risk prostate cancer. However, this hypothesis will need
to be tested in future prospective trials. It is encouraging that in
a pooled analysis of patients with prostate cancer treated with
hypo-fractionated CK, a 5-year PSA relapse-free survival of 81%
was suggested for high-risk patients.
ROLE OF BRACHYTHERAPY IN RADIATION DOSE
ESCALATION IN PATIENTS WITH HIGH-RISK PROSTATE
CANCER
Brachytherapy may be the ideal modality of radiation dose esca-
lation for prostate cancer either alone or as a boost. The radioac-
tive seeds or high dose rate (HDR) brachytherapy catheters are
inserted inside the prostate, thus prostate motion is not an issue for
brachytherapy compared to external beam radiation. In addition,
the radiation dose decreases proportionally to the square of the
distance away from the radioactive sources and allows significant
sparing of the rectum and bladder. Because of the risk of extra-
capsular extension of the tumor, brachytherapy is frequently given
as a boost following external beam radiation, but brachytherapy
without external beam radiation has been reported with excel-
lent local control and survival in selected studies when combined
with androgen deprivation therapy (35–37). A higher dose to the
prostate ranging from 10,000 to 12,000 cGy may be achieved as
a boost after external beam radiation with low dose rate (LDR)
brachytherapy (38, 39). As a result, long-term biochemical-free
survival has been observed with LDR brachytherapy boost for
high-risk prostate cancer (40). Brachytherapy with HDR begins
to play a prominent role in the management of high-risk prostate
cancer because of the technical issues associated with LDR perma-
nent seeds implant: discrepancy between planned and actual seeds
distribution, inability to correct seeds position or to optimize the
dose delivered once the seeds are in place, which may be related
to the radiation oncologist technical skills. The HDR catheters are
relatively easy to visualize with US and may be safely implanted
outside the prostate capsule and into the seminal vesicles without
the risk of seeds migration. Uncertainty over target dose associ-
ated with prostate volume changes, which occurs following LDR
seeds implant is not an issue with HDR brachytherapy. Perhaps the
most important advantage of HDR over LDR brachytherapy is the
real time dose modulation, which provides immediate feedback to
the physician and physicist for optimal catheter distribution and
dwell time. Preliminary results of HDR monotherapy or com-
bined with external beam radiotherapy were very encouraging
with excellent biochemical-free survival and acceptable toxicity
(35–37, 41, 42). Dose escalation with HDR boost after external
beam radiotherapy was feasible and was reported to be associ-
ated with a higher biochemical-free survival in high-risk prostate
cancer patients (43, 44). As most studies reported 3D-CRT with
HDR brachytherapy, it would be interesting to combine IGRT and
HDR brachytherapy for high-risk prostate cancer to decrease long-
term complications in future prospective studies. Nevertheless,
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brachytherapy is an invasive procedure with its complications and
may not be indicated for all patients. The optimal radiation dose
for disease control in high-risk prostate cancer has not been elu-
cidated when combined with androgen deprivation therapy and
needs to be investigated in future clinical trials.
CURRENT CONTROVERSIES IN THE MANAGEMENT OF
HIGH-RISK PROSTATE CANCER
ROLE OF PELVIC RADIOTHERAPY IN THE TREATMENT OF HIGH RISK OF
PROSTATE CANCER
As high-risk prostate cancer patients may have occult pelvic lymph
nodes metastases that are not detected with current diagnostic
technologies, pelvic lymph nodes irradiation may improve loco-
regional control and survival. However, these patients also received
androgen deprivation therapy that may affect micrometastases.
On the other hand, treating the prostate and seminal vesicles only
allows radiation dose escalation without the toxicity of pelvic irra-
diation. Radiation dose escalation from 64 to 74 Gy to a local field
with 3D-CRT and neoadjuvant androgen deprivation has been
reported to improve biochemical-free survival in a randomized
study (45). Using the Roach formula to estimate the risk of pelvic
lymph nodes metastases, a matched-pair analysis did not report
the benefit of adding pelvic radiotherapy in patients at high risk
(>15%) of lymph nodes metastases (46). Two randomized studies
also corroborated the lack of survival benefit when the pelvis was
radiated compared to irradiation of the prostatic bed only (47,
48). As an illustration, excellent local control and survival were
observed in studies where HDR brachytherapy to the prostate were
combined with hormonal therapy without pelvic irradiation (35–
37, 49). The rate of distant metastases or pelvic failures did not
increase in those studies. Thus, pelvic irradiation may not be nec-
essary for high-risk prostate cancer when combined with androgen
deprivation therapy and may increase treatment toxicity because
of the increased volume of normal tissues in the radiation fields.
PROSTATE MOTION AND OPTIMAL PTV FOR IGRT
Prostate motion depends on rectal and bladder filling. In the
supine position for treatment, prostate position is less affected
by bladder filling because of bladder extension anteriorly. How-
ever, in the prone position, pressure on the bladder may push
the prostate posteriorly and the prostate position is affected by the
patient breathing pattern (50). Prostate motion ranged from 1.5 to
3.7 mm, 0.7 to 1.9 mm, and 1.4 to 3.6 mm in the antero-posterior
(AP), left-to-right (LR), and superior–inferior (SI) dimension,
respectively (51–55). The magnitude of prostate motion also
depends on the individual patient. Choice of a PTV also depends
on whether the institution includes pelvic lymph node irradiation
or not as it would be difficult to tract the motion of two inde-
pendent systems. In that sense, radiation dose escalation would
be technically easier without pelvic irradiation. PTV margins for
the lymph nodes may need to be enlarged to avoid under dosing
the pelvic lymph nodes if the set up needs to change because of
prostate motion secondary to rectal filling. The choice of the PTV
margins also depends on the prostate tracking system used by the
institution, either with FM or electromagnetic transponders (inva-
sive method), or with soft tissue fusion based on CBCT or MVCT.
For the non-invasive method, once an optimum PTV has been
selected by the institution, adaptive therapy performed for the first
week or two of treatment based on observed prostate motion on
an individual patient may allow the clinician to reduce the PTV for
example if the established PTV may be too generous. These efforts
may reduce interfraction motion but will not reduce intrafrac-
tion motion that occurs during treatment. Unless the institution
uses an online tracking system for treatment delivery such as the
robotic CK, PTV margins should take into account intrafraction
motion, which may be dependent on treatment time. The use of
an endorectal balloon may decrease intrafraction prostate motion
and may reduce further rectal dose by pushing the posterior rectal
wall away from the high dose area (56). Another factor to take
into consideration is the deformation of the prostate, which may
be related to peristalsis, degree of pelvic musculature contrac-
tion, and breathing pattern. Any prospective trial on radiation
dose escalation should take into consideration the degree prostate
deformation during treatment as under dosing of the prostate may
occur in patients with a large degree of prostate deformation (more
than 10% of prostate volume) (57).
In summary, PTV margins should be determined by the type of
IGRT image tracking and radiation treatment delivery. For exam-
ple, published recommended LR, AP, and SI margins ranged from
3.6, 3.7, and 3.7 mm and 2.46, 2.28, and 2.56 mm for FM and
CBCT, respectively (58, 59).
DOSE PRESCRIPTION COMPARISON AMONG INSTITUTIONS USING
PROSTATE IGRT
Currently, there is no standard recommendation on how to pre-
scribe radiation dose for patients undergoing prostate IGRT. Each
institution set up a specific protocol making dose comparison dif-
ficult among various institutions to assess long-term local control,
and complications. In addition, there were different dose sched-
ule fractionation, and various PTV margins based the technology
used for image tracking. As an illustration, Norkus et al. (24)
reported the following protocol in a randomized study of dose
escalation using hypofractionation and CBCT for image guid-
ance. The prostate PTV was treated to a total dose of 76 Gy at
2 Gy/fraction and 63 Gy at 3.15 Gy/fraction, respectively, with a
PTV margin of 10 mm except posteriory (7 mm). The dose was
optimized so that 95–108% of the PTV received the prescribed
dose. On the other hand, Takeda et al. (17) treated the prostate
PTV to a total dose of 80 Gy in 2 Gy/fraction using FM with a PTV
margin of 5 mm except posteriorly (3 mm). The dose was pre-
scribed to cover 95% of the target volume. At another institution,
even though FM was used for image guidance, the prostate PTV
margin was 10 mm except posteriorly (6 mm). The prescribed dose
was 86.4 Gy to a maximum isodose encompassing the PTV (60).
As the preliminary results from these institutions are excellent for
local control with acceptable toxicity, it would be very difficult to
set up a standard recommendation for PTV margins and dose.
FUTURE DIRECTIONS OF IMAGE-GUIDED RADIOTHERAPY
FOR RADIATION DOSE ESCALATION IN PATIENTS WITH
HIGH-RISK PROSTATE CANCER
Patient with high-risk prostate cancer often have a heterogeneous
tumor distribution within the prostate with areas of concen-
trated cancer cells responsible for disease recurrence following
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radiotherapy (61). These intra-prostatic tumor nodules may
require a higher dose to achieve local control. The conventional
radiotherapy technique with IMRT or IGRT for prostate cancer
consists of a homogeneous radiation dose distribution within
the prostate. Thus, previous studies of radiation dose escalation
increased the total dose to the prostate, which may account for the
risk of late GI and GU complications. New imaging techniques
such as diffusion-weighted (DW), MRI, magnetic resonance spec-
troscopy (MRS),and positron emission tomography (PET)-CT are
more accurate for detection of these intra-prostatic tumor nod-
ules and may allow for radiation dose escalation within the prostate
(62–64). Dosimetric studies suggest that radiation dose escalation
for intra-prostatic tumors nodules with IGRT is feasible and may
allow significant reduction of the rectal dose (65). In a clinical
study of 118 patients with prostate cancer, the GTV defined by
MRI or MRS was treated to 80–81 Gy while the prostate dose was
limited to 78 Gy with IMRT. No patients developed grade 3–4 GI
toxicity (66). Thus, IGRT may be a promising technique for radia-
tion dose escalation on intra-prostatic nodules as significant rectal
toxicity has been observed in patients who had hypo-fractionated
IGRT up to 50 Gy in 10 Gy/fraction (67).
CONCLUSION
Image-guided radiotherapy is a promising technique to reduce
treatment toxicity in patients with early stage high-risk prostate
carcinoma and may improve biochemical-free survival associated
with radiation dose escalation. Reduced treatment time with hypo-
fractionated IGRT may improve patient QOL as they will have
more time to spend with their family. Future clinical trials focused
on improving tumor imaging with MRI, MRS, and PET-CT to
reduce long-term complications associated with high dose prostate
irradiation are warranted.
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